Status:
COMPLETED
A Safety and Tolerability Evaluation of Two 10-Week Dose Regimens of Orally-Administered PF-04494700 in Alzheimer's Patients
Lead Sponsor:
Pfizer
Collaborating Sponsors:
Trans Tech Pharmaceuticals
Conditions:
Alzheimer Disease
Eligibility:
All Genders
50+ years
Phase:
PHASE2
Brief Summary
A 10-week safety and tolerability study of a potential treatment for mild to moderate Alzheimer's disease.
Eligibility Criteria
Inclusion
- Diagnosis of probably Alzheimer's disease for at least 1 year.
- Mini Mental State Exam (MMSE) score between 12-26 at screening.
- Participants must be receiving a cholinesterase inhibitor and/or memantine for at least 4 months, and on a stable dose for at least 2 months.
Exclusion
- Current evidence of a neurological or psychiatric illness that could contribute to dementia.
- Living alone.
- Poorly controlled high blood pressure.
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT00141661
Start Date
October 1 2005
End Date
June 1 2006
Last Update
August 20 2009
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Sun City, Arizona, United States, 85351
2
Pfizer Investigational Site
Fresno, California, United States, 93720
3
Pfizer Investigational Site
San Diego, California, United States, 92103
4
Pfizer Investigational Site
San Francisco, California, United States, 94118